-
Russian barrage on Ukraine kills 15, wounds dozens more
-
Trump warns Iran to open Hormuz or get 'hit very hard'
-
South Korea police raid Starbucks HQ over 'Tank Day' fiasco
-
Factories shed workers in Bangladesh garment sector
-
Tech back in fashion as Asian markets extend rebound
-
North Korea warns of 'military options' over Japan rearmament
-
Total eclipse gives scientists chance to probe Sun's mysteries
-
Tiny light, big dream: Harvesting power from soil in Japan
-
What to know about the total solar eclipse on August 12
-
Trump admin to review 'closed' AI models before release: reports
-
'Like the end of the world': the eclipse chasers flocking to Spain
-
De Minaur fights past Duckworth in all-Aussie Montreal battle
-
Taiwan begins military drills as China pressure grows
-
High bills, cheap panels drive a Philippine solar surge
-
UK mansion where 'listeners' spied on Nazi generals becomes museum
-
Russian barrage on Ukraine kills 2, wounds dozens more
-
Sabalenka tops Uchijima in WTA Toronto opener
-
Alcaraz withdraws from Cincinnati Masters with wrist injury
-
Kgatlana strikes as South Africa reach WAFCON quarter-finals
-
SpaceX revenue jumps 92% in first earnings report, but shares slide
-
Pakistan close on series-levelling win against West Indies
-
US eyes Hormuz deal 'today or tomorrow' as ship sinks in Red Sea
-
Paramount CEO says politics fueling Warner Bros. merger battle
-
SpaceX revenue jumps 92% in first earnings report
-
Trump's sale of access to Truth Social raises eyebrows
-
New commissioner Berg wants to take MLS to 'next level'
-
SpaceX rocket stage expected to slam into Moon
-
Colombian ex-guerrillas fear for future under hardline president
-
US hopeful Hormuz strait deal will be done 'today or tomorrow'
-
Tsitsipas comeback continues with Montreal first-round win
-
Michigan primary puts Democratic divide on the ballot
-
Swiatek fends off Bejlek to reach Toronto third round
-
South Africa captain Kolisi to make Test return in Argentina
-
Reusser romps to overall lead at Tour de France Femmes
-
Cuba's famed resilience comes at a growing mental cost
-
McDonald's reports slower US sales in 2nd quarter
-
Swiss Reusser wins Tour de France Femmes time-trial
-
Arsenal step up bid to sign Newcastle's Guimaraes: reports
-
Hundreds flee homes after Guatemala's Fuego volcano erupts
-
Gazans hold mass funeral for those killed during war
-
Thousands pay tribute to Italian football legend Baresi
-
WHO pleads for more support to tackle Ebola outbreak
-
Oil drops, stocks hit records on hopes of Hormuz opening
-
Oil drops, stocks gain on hopes of Hormuz opening
-
Renard returns as Ivory Coast coach
-
Infantino faces nervy times to see if challenger emerges
-
Italian garbagemen help recover lost 1 mln euro lottery ticket
-
Greece gains ground against blaze near Athens
-
EU nations patch things up after Ceuta migration discord
-
Oil turns lower, stocks gain on hopes of Hormuz opening
Abortion pill mifepristone: timeline of US access
Mifepristone, a drug widely used in the United States to induce abortion in women pregnant for 10 weeks or less, has become a target of the country's anti-abortion movement.
On April 7, a federal judge in Texas ruled in favor of a group challenging the decades-old authorization of mifepristone by the US Food and Drug Administration (FDA).
Here it is a timeline of drug's history and the recent US legal fight likely to end up in the Supreme Court:
- Development and distribution -
- 1980: Mifepristone is developed by French researchers, initially dubbed RU-486 based on its chemical compound.
- 1988: Mifepristone is approved for medical abortions in France, and is adopted in other countries in the years following.
- 2000: The FDA rules mifepristone safe for use in the United States to terminate pregnancies up to seven weeks gestation. It can only be dispensed to users directly at clinics, doctor's offices and hospitals.
- 2016: The FDA says mifepristone can be prescribed for pregnancies up to 10 weeks gestation.
- 2020-21: The FDA halts enforcement of the in-person dispensing requirements due to the Covid-19 pandemic, allowing mifepristone to be mailed to patients after telemedicine consultations.
- Roe v. Wade overturned -
- June 24, 2022: The Supreme Court overturns the landmark Roe v. Wade decision that guaranteed women's abortion rights nationwide. The ruling permits individual states to set their own rules, and about half of the 50 states either ban or tightly restrict the procedure. Mifepristone quickly becomes a new target for anti-abortion activists.
- January 3, 2023: The FDA rules that the drug can be distributed to users by certified pharmacies, including by mail.
- April 7, 2023: A federal judge in Texas places a nationwide ban, to begin after a week-long delay, on distribution of mifepristone while he hears a lawsuit by anti-abortion activists challenging the FDA's 2000 approval of the drug.
- April 12, 2023: A federal appeals court partially overturns the Texas judge's action, saying that it was far too late for plaintiffs to challenge the FDA's 2000 approval of the drug. But the appeals court accepts the judge's block on the 2016 FDA decision to expand mifepristone use up to 10 weeks gestation, and its decision to allow distribution by mail.
- April 13, 2023: The US Justice Department under Democratic President Joe Biden announces it will file an emergency request to the Supreme Court seeking a reversal of the appeals court's decision placing new restrictions on mifepristone.
Y.Bouchard--BTB